Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Drug management of epilepsy in the elderly presents unique but data on this population are scarce. This study aimed to assess the effectiveness and tolerability of perampanel (PER) used as only add-on to a background anti-seizure medication (ASM) in the elderly in a real-world setting.
Methods: We performed a subgroup analysis of patients aged ≥65 years included in a previous 12-month multicenter study on adults. Treatment discontinuation, seizure frequency, and adverse events were recorded at 3, 6 and 12 months after PER introduction. Sub-analyses by early (≤1 previous ASM) or late PER add-on were also conducted.
Results: The sample included 65 subjects (mean age: 75.7 ± 7.2 years), with mainly focal (73.8%) epilepsy. The mean PER daily dose was ≈4 mg during all follow-up. Retention rates at 3, 6, and 12 months were 90.5%, 89.6%, and 79.4%ly. The baseline median normalized per 28-day seizure number significantly decreased at 3-, 6- and 12-month visits. One year after PER introduction, the responder rate (≥50% reduction in baseline seizure frequency) was 89.7%, with a seizure freedom rate of 72.4%. Adverse events occurred in 22 (34.9%) patients with dizziness and irritability being the most frequent. No major differences between early (41 patients, 63.1%), and late add-on groups were observed.
Conclusion: Adjunctive PER was effective and well-tolerated when used as only add-on treatment in elderly people with epilepsy in clinical practice, thus representing a suitable therapeutic option in this age category.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2023.122797 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of perampanel as the only adjunctive anti-seizure medication in adults: Final results from the observational PERPRISE study in Germany.
Epilepsia Open
August 2025
Department of Neurology, University of Saarland, Homburg, Germany.
Objective: The PERPRISE study (Study 509; NCT04202159) was a prospective, observational, non-interventional study in a real-world setting in Germany. This study was conducted to evaluate the effectiveness of perampanel as the only adjunctive treatment for 12 months in patients aged ≥18 years with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) in clinical practice.
Methods: Adult patients with FBTCS or GTCS received perampanel as an adjunctive therapy to anti-seizure medication (ASM) monotherapy (add-on therapy) or as a substitute for one ASM in dual therapy (substitution therapy) per the approved indication.
Treatment of epilepsy using newer antiseizure medications: A retrospective cohort study of prescription patterns in Sweden 2013-2022.
Epilepsia
August 2025
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Objective: This study aimed to analyze the choice of newly introduced antiseizure medications (ASMs; brivaracetam, cannabidiol, cenobamate, fenfluramine, and perampanel) by age and sex, and the use of these ASMs in relation to regulatory approval.
Methods: Patients were identified with dispensation of any ASM subsequent to at least one health care contact due to epilepsy (International Classification of Diseases, 10th Revision: G40) during 2000-2022. Incidence rate ratios (IRRs) for starting a newly introduced ASM, retention rates, number of ASM treatments preceding the first dispensation of a new ASM and concurrent ASM treatments at first dispensed new ASM, and share of patients using new ASMs as adjunctive treatment were calculated.
Effectiveness of perampanel as only concomitant antiseizure medication for highly active epilepsy: insight from a real-world, multicenter retrospective study.
J Neurol
June 2025
Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy.
Introduction: Managing patients with highly frequent seizures poses significant challenges for clinicians due to their high resistance to therapy. This study aims to evaluate the 12-month efficacy, safety, and tolerability of PER as the sole add-on therapy for patients with highly active epilepsy in a real-world setting.
Methods: Data from the previous Italian retrospective, observational, multicenter "PERampanel as Only Concomitant Antiseizure Medication" (PEROC) study were analyzed, categorizing patients by baseline seizure frequency into three groups: < 5, 5-20, and > 20 seizures/month.
Perampanel as Add-on in Patients Aged ≥ 12 Years with Focal Epilepsy: A Prospective Real-World Observational Study from Southern China.
Neurol Ther
August 2025
Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Introduction: This study aimed to evaluate the effectiveness, tolerability and safety of perampanel (PER) as an add-on therapy for southern Chinese patients aged ≥ 12 years with focal epilepsy.
Methods: This prospective cohort study enrolled consecutive patients with focal epilepsy treated between January 2023 and January 2024. Patients received PER as add-on therapy, with medication adjustments, seizure frequency and adverse events (AEs) monitored at 3, 6, 9 and 12 months.
Efficacy and tolerability of perampanel as add-on therapy in Dravet syndrome: A prospective real-world study.
Epilepsia Open
August 2025
Department of Neurology, Shenzhen Children's Hospital, Shenzhen, China.
Objective: To investigate the efficacy and tolerability of perampanel (PER) on Dravet syndrome in China by a prospective real-world study.
Methods: We prospectively enrolled children with Dravet syndrome from the neurology clinic of Shenzhen Children's Hospital from September 2020 to October 2021. The average monthly seizure frequency within 2 months before enrollment was recorded as the baseline.